British Journal of Haematology. Risk factors for cancer-associated venous thromboembolism in outpatient DVT clinics
|
|
- Paul Foster
- 5 years ago
- Views:
Transcription
1 Risk factors for cancer-associated venous thromboembolism in outpatient DVT clinics Journal: Manuscript ID: BJH R Manuscript Type: Letters Date Submitted by the Author: n/a Complete List of Authors: Rose, Peter; University Hospital Coventry and warwickshire, Haematology McManus, Aidan; MMRx Consulting, Research Arya, Roopen; King's College Hospital, Haematology Scriven, Nicholas; Calderdale Royal Hospital, MAU Farren, Timothy; Barts and The London Hospitals, Haematology Nokes, Timothy; Derriford Hospital, Haematology Bacon, Sue; Scarborough Hospital, Haematology Cooper, Derek; Independent Consultant, Statistics O'Shaughnessy, Denise; Department of Health, Blood Policy Paneesha, Shankara; Birmingham Heartland Hospital, Haematology Key Words: THROMBOSIS, RISK FACTORS, CANCER
2 Page of Risk factors for cancer-associated venous thromboembolism in outpatient DVT clinics Peter Rose, Aidan McManus, Roopen Arya, Nicholas Scriven, Timothy Farren, Tim Nokes, Sue Bacon, Derek Cooper, Denise O'Shaughnessy, Shankaranarayana Paneesha 0 Consultant, Department of Haematology, Warwick Hospital, Warwick, UK; Director, MMRx Consulting, Cheam, Surrey, UK; Consultant, Department of Haematology, King's College Hospital, London, UK; Consultant, Medical Assessment Unit, The Calderdale Royal Hospital, Halifax, UK; Clinical Scientist, Department of Haematology, Barts and The London School of Medicine and Dentistry, London, UK; Consultant, Department of Haematology, Derriford Hospital, Plymouth, UK; Thrombosis Nurse Specialist, North Bristol NHS Trust, Bristol, UK; Statistical Consultant, London, UK; Special Advisor, Blood Policy Unit, Department of Health, London, UK; 0 Consultant Department of Haematology, Heart of England NHS Foundation Trust, Birmingham, UK. Correspondence to: Dr Peter Rose, Department of Haematology, Warwick Hospital, Lakin Road, Warwick CV BW Tel: 0 x 0; Peter.Rose@swh.nhs.uk Funding/Support: The VERITY registry is funded by sanofi-aventis Conflict of interest: Aidan McManus has received consultancy fees from sanofi-aventis
3 Page of Venous thromboembolism (VTE) in cancer patients is increasingly frequent (Khorana et al, 00), is associated with worse survival (Paneesha et al, 00) and its treatment poses particular challenges (Noble, 00), including increased bleeding and recurrence risks. A number of important factors influence thrombotic risk, including site of cancer, presence of metastatic disease and certain chemotherapy and hormonal treatment regimens (Wun and White, 00), but for most types of cancer, there are few data describing the occurrence or relevance of common VTE risk factors and it is not clear to what extent major risk factors such as surgery or previous history of VTE impact the risk already associated with the presence of cancer. This is particularly the case for ambulant cancer patients. While there have been attempts to identify cancer outpatients at high-risk of chemotherapy-associated VTE (Khorana et al, 00), there is a paucity of data on risk factors that might allow identification of those cancer patients most at risk of VTE. In this analysis of patients seen at outpatient DVT clinics, we wished to determine if the incidence of established VTE risk factors differed in patients with VTE according to cancer status (cancer diagnosis vs. no cancer diagnosis). The presence of seven established risk factors for VTE (Arya et al, 00) was compared in cancer and non-cancer patients with confirmed VTE using the χ test with Yates correction. All analyses were conducted using a commercial software package (SPSS version ; SPSS Inc., Chicago, Ill, USA). The risk factors were medical inpatient history or immobilization for more than days within the last weeks, major surgery in the last weeks, hormonal risk (use of hormone-replacement therapy or oral contraceptives; pregnant or post-partum), personal history of VTE, known thrombophilia, intravenous drug abuse and current smoking, as previously described (Arya et al, 00). The data set has been described previously (Paneesha et al, 00). VERITY (VEnous thromboembolism RegIsTrY) is an ongoing prospective registry of patients attending outpatient DVT clinics. A variety of algorithms, mainly based on D-dimer measurement and pre-test probability, are used to exclude VTE. Confirmatory, objective testing is undertaken according to local protocols,
4 Page of usually including ultrasonography or venography for suspected DVT and pulmonary angiography, lung scintigraphy or helical computed tomography for suspected PE. Cancer (current or having received treatment for cancer in the last months) is recorded as one of specific cancer types [bone/sarcoma, breast, central nervous system (CNS), colorectal, endocrine, gynecologic, head/neck, leukemia, lung, lymphoma, melanoma, myeloma, non-melanoma, pancreas, prostate, urological, upper gastrointestinal (GI)] with other. No record is made of metastatic disease, but patients with multiple cancer sites are recorded; no histological description, tumour grade or cancer stage are recorded. In addition, a detailed history of the cancer patients is not recorded, some of whom may have been hospitalized during their care and only briefly used the outpatient service. Of, patients enrolled in VERITY by UK hospitals, 0,0 (.%) had confirmed VTE; (.%) were recorded as having cancer. % of the non-cancer VTE cases were female, compared with % of the cancer VTE patients. Patients with cancer were significantly older than cancer-free VTE cases (. ±. vs.. ±. years; p<0.000) (Paneesha et al, 00). Breast, prostate, colorectal and lung cancer were the most common cancers accounting for.% of the cancerassociated VTE cases (Paneesha et al, 00). Data on the seven established VTE risk factors were available in -% of cases (numbers are shown in Table ). Cancer-associated thrombosis cases were more likely to have experienced a medical inpatient stay/immobilization (.% vs 0.%; χ =.; p<0.00), but less likely to have a history of VTE (.0% vs.%; χ =.; p<0.00), thrombophilia (0.% vs.%; χ =0.; p=0.00), intravenous drug abuse (0.% vs.%; χ =0.; p<0.00) and to smoke (.% vs.%; χ =.; p<0.00) than cancer-free cases; there was no difference in hormonal risk and recent surgery (see Table ). This analysis of an observational registry that enrolled more than 0,000 patients with VTE at outpatient DVT clinics showed that established VTE risk factors previous history of VTE, thrombophilia, IV drug abuse and smoking were less common in patients with cancer-associated VTE. Of the seven risk factors compared, the only risk factor more common in patients with cancer
5 Page 0 of was a medical in-patient stay/immobilization, despite the finding that patients with cancer were significantly older than cancer-free VTE cases. Identification of cancer patients most at risk of VTE is an important clinical goal. Previously, we reported extreme differences in VTE risk associated with different cancer sites in this patient cohort (Paneesha et al, 00). Taken together with our current findings, we suggest that established risk factors for VTE, such as previous thrombosis history, are of less importance than cancer site when assessing the risk of cancer-associated VTE. Our results may be relevant to the design of future studies of risk algorithms for VTE prevention in cancer patients in the outpatient setting.
6 Page of References Arya R, Paneesha S, McManus A, Parsons N, Scriven N, Farren T, Nokes T, Smith H, O'Shaughnessy D, Rose P (00) More on thromboprophylaxis: Quantifying risk for venous thromboembolism. Thrombosis and Haemostasis, 0, -. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (00) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer, 0,. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (00) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood, :0-0. Noble S. The challenges of managing cancer related venous thromboembolism in the palliative care setting (00) Postgraduate Medicine Journal,, -. Paneesha S, Lokare A, Lester Z, Nokes T, Arya R, Farren T, Scriven N, McManus A, O'Shaughnessy D, Rose P (00) Impact of venous thromboembolism on survival in patients with malignancy. British Journal of Haematology,, -0. Paneesha S, McManus A, Arya R, Scriven N, Farren T, Nokes T, Bacon S, Nieland A, Cooper D, Smith H, O'Shaughnessy D, Rose P. Frequency, demographics and risk (according to tumor type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics (00) Thrombosis and Haemostasis, 0, -. Wun T, White RH (00). Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Investigations, (Suppl ), -.
7 Page of Table. Statistical analysis of risk factors in VTE patients according to cancer status Risk factor More common in cancer patients No difference More common in non-cancer patients Medical inpatient history/immobilization > days within last weeks weeks risk* history of VTE abuse smoking Patients, N Cancer patients.%.%.%.0% 0.% 0.%.% Non-cancer patients 0.% 0.%.%.%.%.%.% χ *Use of hormone-replacement therapy or oral contraceptives; pregnant or post-partum. Major surgery in last Hormonal Personal Thrombophilia IV drug Current DF p <0.00 <0.0 <0. < <0.00 <0.00
Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics
338 Schattauer 2010 Blood Coagulation, Fibrinolysis and Cellular Haemostasis Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient
More informationThromboembolism and cancer: New practices. Marc Carrier
Thromboembolism and cancer: New practices Marc Carrier Marc Carrier Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board Leo Pharma, BMS No relevant
More informationRISK FACTORS. Cancer type. Cancer stage
CANCER ASSOCIATED THROMBOSIS RISK FACTORS The link between cancer and thrombosis is well established, with malignancy recognised as the most important individual risk factor for venous thromboembolism
More informationPRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES
PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES Mario Mandalà, MD Unit of Clinical Research Department of Oncology and Haematology Papa Giovanni XXIII Hospital Cancer Center
More informationVTE Risk Assessment. Challenges of Hemostasis in Cancer Patients. Cihan Ay, MD Associate Professor
Challenges of Hemostasis in Cancer Patients VTE Risk Assessment Cihan Ay, MD Associate Professor Clinical Division of Haematology and Haemostaseology Department of Medicine I, Comprehensive Cancer Center
More informationManagement of Cancer Associated Thrombosis (CAT) where data is lacking. Tim Nokes Haematologist, Derriford Hospital, Plymouth
Management of Cancer Associated Thrombosis (CAT) where data is lacking Tim Nokes Haematologist, Derriford Hospital, Plymouth Contents Overview of the statistics and aetiology for Cancer Associated Thrombosis
More informationIs There a Role for Prophylaxis in Cancer Patients During Therapy?
Victor F. Tapson, MD, FCCP, FRCP Professor of Medicine Director, Center for Pulmonary Vascular Disease Division of Pulmonary and Critical Care Duke University Medical Center Durham, N.C. USA Is There a
More informationAnticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism
Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism Annie Young PhD Professor of Nursing, University of Warwick, UK on behalf of the select-d Collaborative
More informationCancer and Thrombosis
Cancer and Thrombosis The close relationship between venous thromboembolism and cancer has been known since at least the 19th century by Armand Trousseau. Thrombosis is a major cause of morbidity and mortality
More informationProphylaxie primaire sur le patient ambulatoire. Marc Carrier
Prophylaxie primaire sur le patient ambulatoire Marc Carrier Marc Carrier In compliance with COI policy, SSVQ requires the following disclosures to the session audience: Research Support/P.I. Employee
More informationCancer Associated Thrombosis
Cancer Associated Thrombosis Can we use DOACs? D R. C Y N T H I A W U MD F R C P ( C ) D I V I S I O N O F H E M A T O L O G Y F A M I L Y P H Y S I C I A N S A N D C A N C E R C O N T R O L A P R I L
More informationIn the Clinic: Annals Sweta Kakaraparthi 1/23/15
In the Clinic: Annals Sweta Kakaraparthi 1/23/15 Case Scenerio 56 year old female with breast cancer presents to the clinic for her 3 month followup! She is concerned about blood clots and asks you about
More informationPulmonary Embolism. Pulmonary Embolism. Pulmonary Embolism. PE - Clinical
Pulmonary embolus - a practical approach to investigation and treatment Sam Janes Wellcome Senior Fellow and Respiratory Physician, University College London Background Diagnosis Treatment Common: 50 cases
More informationPost Reproductive Health Joint RCOG/BMS Meeting Wednesday 31 October _ Thursday 1 November 2018
Post Reproductive Health Joint RCOG/BMS Meeting Wednesday 31 October _ Thursday 1 November 2018 Overview This meeting endeavours to provide answers to the most commonly asked and most difficult questions
More informationVTE Dublin th-14th September 2018 Hogan Suite - Croke Park, Dublin. Wednesday 12th September. Thursday 13th September.
12th-14th September 2018 Hogan Suite - Croke Park, Dublin 0900-1200 Co-ordinated by Tomás Breslin Consultant in Emergency Medicine Mater Misericordiae University Hospital Workshops comprise 10 ultrasounds
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationDr. Pierpaolo Di Micco Internal Medicine and Emergency Room Fatebenefratelli Hospital of Naples, Italy
? Para què sirve el recuento de leucocitos en lospacientescon cancer? Dr. Pierpaolo Di Micco Internal Medicine and Emergency Room Fatebenefratelli Hospital of Naples, Italy ? Para què sirve el recuento
More informationProper Diagnosis of Venous Thromboembolism (VTE)
Proper Diagnosis of Venous Thromboembolism (VTE) Whal Lee, M.D. Seoul National University Hospital Department of Radiology 2 nd EFORT Asia Symposium, 3 rd November 2010, Taipei DVT - Risk Factors Previous
More informationPROGNOSIS AND SURVIVAL
CANCER ASSOCIATED THROMBOSIS PROGNOSIS AND SURVIVAL Since French internist Armand Trousseau reported the occurrence of mysterious thrombotic disorders in cancer patients in the mid-19th century, the link
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationDave Duddleston, MD VP and Medical Director Southern Farm Bureau Life
Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Sources of Risk for Venous Diseases Pulmonary embolism (thrombus) Bleeding from anticoagulation Mortality from underlying disease Chronic
More informationASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation
ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation Stephan Moll Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of
More informationTHROMBOPROPHYLAXIS IN CANCER PATIENTS
CANCER ASSOCIATED THROMBOSIS THROMBOPROPHYLAXIS IN CANCER PATIENTS Cancer is an important risk factor for venous thromboembolism (VTE). Research has shown that 4-20% of 1 patients with cancer experience
More informationDiagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Summary Number 68 Overview Venous thromboembolism
More informationNational Cancer Patient Experience Programme National Survey. South Tees Hospitals NHS Foundation Trust. Published September 2014
National Cancer Patient Experience Programme 2014 National Survey South Tees Hospitals NHS Foundation Trust Published September 2014 The National Cancer Patient Experience Survey Programme is undertaken
More informationWales Cancer Patient Experience. Survey Aneurin Bevan University Health Board. Published January 2014
Wales Cancer Patient Experience Survey 2013 Aneurin Bevan University Health Published January 2014 The Wales Cancer Patient Experience Survey was undertaken by Quality Health on behalf of the Welsh Government
More informationNational Cancer Patient Experience Programme National Survey. Royal National Orthopaedic Hospital NHS Trust. Published September 2014
National Cancer Patient Experience Programme 2014 National Survey Royal National Orthopaedic Hospital NHS Trust Published September 2014 The National Cancer Patient Experience Survey Programme is undertaken
More informationHandbook for Venous Thromboembolism
Handbook for Venous Thromboembolism Gregory Piazza Benjamin Hohlfelder Samuel Z. Goldhaber Handbook for Venous Thromboembolism Gregory Piazza Cardiovascular Division Harvard Medical School Brigham and
More informationCabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel
Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a
More informationRivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist
More informationCristhiam M. Rojas-Hernandez, MD Assistant Professor of Medicine Section of Benign Hematology
MEASUREMENT OF ADHERENCE, HEALTH- RELATED QUALITY OF LIFE, AND HEALTH- CARE RESOURCE UTILIZATION DURING ANTICOAGULATION THERAPY IN CANCER- RELATED VENOUS THROMBOEMBOLISM Cristhiam M. Rojas-Hernandez, MD
More informationTissue Factor-positive Microparticles in Cancerassociated
Tissue Factor-positive Microparticles in Cancerassociated Thrombosis Nigel Mackman, Ph.D., FAHA John C. Parker Distinguished Professor of Medicine Director of the UNC McAllister Heart Institute Co-Director
More informationEpidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005
Cancer and Venous Thromboembolism Objectives 1. Epidemiology of thrombosis in patients with malignancy 2. Anticancer agents and thrombosis 3. Current treatment protocols at UHN 4. Prevention of DVT 5.
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/188/20915 holds various files of this Leiden University dissertation. Author: Flinterman, Linda Elisabeth Title: Risk factors for a first and recurrent venous
More informationCancer in the South West Peninsula - a baseline assessment
Cancer in the South West Peninsula - a baseline assessment 1 The Cancer Reform Strategy 1.1 The Cancer Reform Strategy, published in December 2007 1, built on the progress already achieved since the publication
More informationINTRODUCTION Indication and Licensing
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: Apixaban (Eliquis ) Transfer of Care document Indication: Treatment of acute venous thromboembolism
More informationNational Cancer Intelligence Network Routes to Diagnosis:Investigation of melanoma unknowns
National Cancer Intelligence Network Routes to Diagnosis:Investigation of melanoma unknowns Routes to Diagnosis: Investigation of melanoma unknowns About Public Health England Public Health England exists
More informationCancer associated thrombosis
Cancer associated thrombosis Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University Take home messages 1. Clots are cool
More informationDVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationAsymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival Clinical Studies
British Journal of Cancer (2012) 107, 1244 1248 All rights reserved 0007 0920/12 www.bjcancer.com Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact
More informationCOSD & Source of Referral
COSD & Source of Referral A Brief guide October 2014 Michael Sharpe Data Improvement Manager National Cancer Registration Service What is COSD? Cancer and Outcomes Services Dataset Clinical dataset for
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationCancer Associated Thrombosis An update.
Cancer Associated Thrombosis An update. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway LIQUID
More informationNational Cancer Patient Experience Programme. 2012/13 National Survey. James Paget University Hospitals NHS Foundation Trust. Published August 2013
National Cancer Patient Experience Programme 2012/13 National Survey Published August 2013 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of NHS
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationNICE Guidance: Venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital 1
The College of Emergency Medicine Patron: HRH The Princess Royal Churchill House Tel +44 (0)207 404 1999 35 Red Lion Square Fax +44 (0)207 067 1267 London WC1R 4SG www.collemergencymed.ac.uk CLINICAL EFFECTIVENESS
More informationThe risk of venous thromboembolism is four to seven times as
review article Dan L. Longo, M.D., Editor Prophylaxis against Venous Thromboembolism in Ambulatory Patients with Cancer Jean M. Connors, M.D. The risk of venous thromboembolism is four to seven times as
More informationNational Cancer Patient Experience Programme. 2012/13 National Survey. East Kent Hospitals University NHS Foundation Trust. Published August 2013
National Cancer Patient Experience Programme 2012/13 National Survey Published August 2013 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of NHS
More informationIs it safe to manage pulmonary embolism in Primary Care? Roopen Arya King s College Hospital
Is it safe to manage pulmonary embolism in Primary Care? Roopen Arya King s College Hospital A few definitions Safe Avoid death, recurrent thrombosis, bleeding Manage Diagnosis + treatment Pulmonary embolism
More informationNational Cancer Patient Experience Programme. 2012/13 National Survey. Milton Keynes Hospital NHS Foundation Trust. Published August 2013
National Cancer Patient Experience Programme 2012/13 National Survey Published August 2013 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of NHS
More informationComparison of Venothromboembolism Prophylaxis Practices in a Winnipeg Tertiary Care Hospital to Chest Guidelines: A Quality Improvement Project
Comparison of Venothromboembolism Prophylaxis Practices in a Winnipeg Tertiary Care Hospital to Chest Guidelines: A Quality Improvement Project Dr. Jonathan Laxton, FRCPC, R5 GIM University of Manitoba
More information2010 National Survey. University College London Hospitals NHS Foundation Trust
National Cancer Patient Experience Programme 2010 National Survey University College London Hospitals NHS Foundation Trust Published January 2011 The National Cancer Patient Experience Survey Programme
More informationCancer Associated Thrombosis
Cancer Associated Thrombosis Pantep Angchaisuksiri, MD Professor of Medicine Mahidol University, Thailand Adjunct Associate Professor University of North Carolina, Chapel Hill, USA Piccioli A. J Thromb
More informationWhat s New in DVT & PE
What s New in DVT & PE Mark Buch MD CM CCFP(EM) Attending physician Emergency Department Jewish General Hospital Family Physician and Medical Director GMF Santé Mont-Royal Objectives: Review the diagnostic
More informationWales Cancer Patient Experience Survey Hywel Dda University Health Board. Published January 2014
Wales Cancer Patient Experience Survey 2013 Hywel Dda University Health Published January 2014 The Wales Cancer Patient Experience Survey was undertaken by Quality Health on behalf of the Welsh Government
More informationCHAPTER 2 VENOUS THROMBOEMBOLISM
CHAPTER 2 VENOUS THROMBOEMBOLISM Objectives Venous Thromboembolism (VTE) Prevalence Patho-physiology Risk Factors Diagnosis Pulmonary Embolism (PE) Management of DVT/PE Prevention VTE Patho-physiology
More informationNew oral anticoagulants and Palliative Care.
New oral anticoagulants and Palliative Care. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationPotpourri of Hematology Oncology. Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy
Potpourri of Hematology Oncology Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy Lifestyle Modifications to Decrease the Risk of Colorectal Cancer Estimates for 2018 American
More informationPulmonary Embolism Pathway
Pulmonary Embolism Pathway Ambulatory Care Pathway Dr. A. Zafar, Dr. A. Rehman, Dr. T. Malik September, 2011. Patient Identification Label Pulmonary Embolism Pathway Clinical History Comments Hospital
More informationVenous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital
Please Note: This policy is currently under review and is still fit for purpose. Venous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital This procedural document supersedes
More information2 Diagnosis and Staging of Cancer 2.1 Pathophysiology of cancer 2.2 Classification and staging 2.3 Diagnostic measures for specific cancer types
Oncology Nursing Sub-Specialty Module Reference: Gobel B. M., Triest-Robertson S. & Vogel W.H. (Eds). (205). Advanced Oncology Nursing Certificate Review and Resources Manual. Pittsburgh: Oncology Nursing
More informationPrimary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Edoxaban is a non-vitamin K antagonist oral
More informationPE service. 65 years old lady. What would you do next? Risk stratification. What would you do next? Regional College Lecture PE Management
PE service Regional College Lecture PE Management Update in medicine (Eastern) Cambridge 29 th June 2017 Dr Rachel M Limbrey DM FRCP University Hospital Southampton NHS Foundation Trust Ambulatory acute
More informationCancer and blood clots
n The Leeds Teaching Hospitals NHS Trust Cancer and blood clots What you should know whilst you are in source isolation Information for thyroid patients Please read this leaflet carefully. It will give
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21764 holds various files of this Leiden University dissertation. Author: Mos, Inge Christina Maria Title: A more granular view on pulmonary embolism Issue
More informationIdentifying and counting people living with treatable but not curable cancer
Identifying and counting people living with treatable but not curable cancer Rachel White Joanna Pethick, Archie Macnair, Gregory Fallica, Jennifer Than and Jane Maher September 2018 Who are the people
More informationUnknown Primary Service for patients at Chesterfield Royal Hospital
Unknown Primary Service for patients at Chesterfield Royal Hospital David Brooks Macmillan Consultant in Palliative Medicine Louise Merriman GP Cancer Lead With thanks to Macmillan Cancer Support, who
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationAllied Healthcare Professionals Module
Allied Healthcare Professionals Module Allied health professionals (AHPs) are key members of today s multidisciplinary healthcare team. They work in partnership with health and social care colleagues across
More informationCRN SWP Business Intelligence Unit
CRN SWP Business Intelligence Unit Name of report: Cancer Update Q3 2017/2018 Release date: 26 th February 2018 Data source(s) used: Portfolio ODP Data cut-off: 1 st January 2018 Brief Summary: Summary
More informationRare Urological Cancers Urological Cancers SSCRG
Rare Urological Cancers Urological Cancers SSCRG Public Health England South West Knowledge & Intelligence Team 1 Introduction Rare urological cancers are defined here as cancer of the penis, testes, ureter
More informationPrevention and treatment of venous thromboembolic disease
REVIEW Prevention and treatment of venous thromboembolic disease SUSAN McNEILL AND CATHERINE BAGOT Awareness of the risk factors for venous thromboembolic (VTE) disease and timely administration of thromboprophylaxis
More informationP-Selectin as Predictor Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
Hiroshima J. Med. Sci. Vol. 67, Special Issue, May, 018 1 P-Selectin as Predictor Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy C. SUHARTI *, SANTOSA, Eko Adhi PANGARSO, Budi SETIAWAN,
More information2010 National Survey. East Kent Hospitals University NHS Trust
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
More information2010 National Survey. The North West London Hospitals NHS Trust
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
More information2010 National Survey. Royal National Orthopaedic Hospital NHS Trust
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
More information2010 National Survey. The Leeds Teaching Hospitals NHS Trust
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
More informationDavid Brooks Macmillan Consultant in Palliative Medicine
Developing a new pathway for CUP patients at Chesterfield Royal Hospital David Brooks Macmillan Consultant in Palliative Medicine Philippa Hughes, Claire Farrington, Bill Noble, Peter Bath, Lingesan Gokulkrishnan,
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More information2010 National Survey. Northern Lincolnshire and Goole Hospitals NHS Foundation Trust
National Cancer Patient Experience Programme 2010 National Survey Northern Lincolnshire and Goole Hospitals NHS Foundation Trust Published January 2011 The National Cancer Patient Experience Survey Programme
More informationTHROMBOSIS RISK FACTOR ASSESSMENT
Name: Procedure: Doctor: Date: THROMBOSIS RISK FACTOR ASSESSMENT CHOOSE ALL THAT APPLY EACH RISK FACTOR REPRESENTS 1 POINT Age 41 60 years Minor Surgery Planned History of Prior Major Surgery (< 1 month)
More informationCancer-associated thrombosis: updates and controversies
THROMBOSIS IN CHALLENGING POPULATIONS Cancer-associated thrombosis: updates and controversies Alok A. Khorana James P. Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester,
More informationDiagnostic Algorithms in VTE
Diagnostic Algorithms in VTE Mark H. Meissner, MD Department of Surgery University of Washington School of Medicine Overutilization of Venous Duplex U/S 1983-1993 (Zweibel et al, Australasian Rad, 1995)
More informationDr Hilary Williams. Consultant in Medical Oncology at Velindre Cancer Centre
Dr Hilary Williams. Consultant in Medical Oncology at Velindre Cancer Centre Hilary.williams4@wales.nhs.uk Thinking about Acute Oncology. Why do we need acute oncology locally? What the Hub VCC provides
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationVenous Thromboembolic Events (VTEs)
Venous Thromboembolic Events (VTEs) This Infosheet explains what a VTE is, what the causes and risk factors for VTEs are, the symptoms of a VTE, how they can be treated and some tips for self-management.
More informationRecurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism
ARTICLES Coagulation & its Disorders Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism Tom van der Hulle, Melanie Tan, Paul L. den Exter, Mark J.G.
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 16 December 1999 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL
More informationWest Midlands Sarcoma Advisory Group
West Midlands Sarcoma Advisory Group Guideline for the Initial Investigation and Referral to Specialist Sarcoma Multi Disciplinary Team for Suspected Bone Sarcoma Version History Version Date Brief Summary
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More informationLANDMARK MEDICAL CENTER CANCER PROGRAM YEAR IN REVIEW 2013
LANDMARK MEDICAL CENTER CANCER PROGRAM YEAR IN REVIEW 2013 Landmark Medical Center offers a comprehensive cancer care services to our patients. LMC Cancer program is committed to ensure that patients receive
More informationWest Midlands Sarcoma Advisory Group
West Midlands Sarcoma Advisory Group Guideline for the Initial Investigation and Referral to Sarcoma Specialist Multi Disciplinary Team for Suspected Sarcoma of Soft Tissue Extremities (limbs and trunk
More information